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Abstract
Objective: To provide accurate estimates of the commencement time, duration and
dosage of folic acid (FA) supplementation taken by Irish women in the
periconceptional period. The study also aimed to establish the factors associated
with optimal FA supplementation practices.
Design: Cross-sectional observational study. Women’s clinical and sociodemo-
graphic details were computerised. Maternal weight and height were measured
before calculating BMI. Detailed FA supplementation questionnaires were
completed under the supervision of a trained researcher.
Setting: A large university maternity hospital, Republic of Ireland, January
2014–April 2016.
Subjects: Women (n 856) recruited at their convenience in the first trimester.
Results: While almost all of the women (97%) were taking FA at enrolment, only
one in four women took FA for at least 12 weeks preconceptionally (n 208).
Among the 44% of women who were supplementing with FA preconceptionally,
44% (162/370) reported taking FA for less than the 12 weeks required to achieve
optimal red-blood-cell folate levels for prevention of neural tube defects. On
multivariate analysis, only planned pregnancy and nulliparity were associated with
taking FA for at least 12 weeks preconceptionally. Among women who only took
FA postconceptionally, almost two-thirds commenced it after day 28 of their
pregnancy when the neural tube had already closed.
Conclusions: As the timing of FA was suboptimal both before and after conception,
we recommend that current national FA guidelines need to be reviewed.
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Neural tube defects (NTD) are a group of congenital neuro-
developmental abnormalities including spina bifida and
anencephaly, which have been shown in two landmark
studies to be potentially preventable by periconceptional
folic acid (FA) supplementation in two-thirds of cases(1,2).
National and international guidelines recommend that all
women planning a pregnancy should take 400µg FA each
day as an oral supplement, starting periconceptionally prior
to the closure of the neural tube which occurs at 3–4 weeks
after conception(3–5). Scientific evidence suggests that the risk
of NTD is substantially attenuated at red-blood-cell (RBC)
folate concentrations of 906–1000nmol/l(6,7). In recent
kinetic studies, it has been shown that it takes 12 weeks of
daily supplementation with 400 µg FA to achieve these levels
of RBC folate at which NTD prevention is optimised(8–10).
Irish studies suggest that 19–44% of women take FA
preconceptionally(11–14). One recent longitudinal study
conducted at our centre has shown that periconceptional
FA supplementation has declined from 45% of women in
2009 to 43% of women in 2013(11). While many Irish
studies have reported on the use of FA supplements, only
two Irish studies have commented on the duration of
preconceptional FA use(12,14). These studies reported that
only one in four women was taking FA for 3 months or
more preconceptionally.
International data suggest that between 10 and 55% of
women use FA preconceptionally(15–17). Cross-sectional
studies from Korea and East London report the lowest
rates of preconceptional FA use(15,17). Ethnic minority groups
have been shown to have lower rates of preconceptional FA
use(18). There is a dearth of studies however investigating
duration of preconceptional FA use. Of those which have
been published, data from the Norwegian Mother and
Baby Study, a longitudinal study, showed that 11·7% of
women took FA for 2 months or more preconceptionally,
while data from a cross-sectional study conducted in
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Quebec, Canada indicated of those women who took FA
preconceptionally, over two-thirds took for ≥12 weeks
preconceptionally(19,20). While a limited number of interna-
tional studies have investigated the timing at which FA
supplementation commences during pregnancy, this
remains an area which is largely under-investigated. Overall,
findings from published studies in this area are variable and
suggest that of those women who begin taking FA post-
conceptionally, 9 to 37% commence taking FA between 4
and 6 weeks postconception(12,15,19). The longitudinal
Norwegian Mother and Baby Study showed that among
women who commenced FA postconceptionally, only 24%
began supplementing in the first month postconception;
with one-third commencing FA in the second month post-
conception and just under half commencing FA after this
point(19). A cross-sectional study conducted in an ethnically
diverse population (50% non-Caucasian) in East London
asked pregnant women about their FA supplementation
practices at that point in their pregnancy. It showed that
of those women who commenced FA postconceptionally,
37% started at less than 6 weeks’ gestation while 63%
started after this point(15). The main Irish study conducted in
this area was a cross-sectional investigation among 214
women. It revealed that of those who started FA post-
conceptionally, only 9% (n 19) commenced supplementa-
tion within the first month after conception(12).
Given the limited Irish data describing the duration of
periconceptional FA supplementation and the rising inci-
dence of NTD in Ireland, examination of the duration of
periconceptional FA supplementation is important. Kinetic
studies have shown that those who consumed 400µg FA/d
reached an RBC folate concentration associated with
optimally reduced risk of NTD after 3 to 6 months(7–9).
Therefore, it is important to establish whether or not women
who take FA preconceptionally are doing so for the required
duration to optimise NTD prevention. For those who do not
take FA preconceptionally, it is important to examine the
stage of pregnancy at which these women commence FA
supplementation given that the neural tube has already
closed by day 28 postconception.
Aside from these timing and duration issues, it is also
important to determine the dose of FA used by women
attending their first antenatal visit, to estimate the duration
of FA supplementation required to optimise folate levels
for NTD prevention.
The objective of the present study was to provide
accurate estimates of the commencement time, duration
and dosage of FA supplementation taken by Irish women
in the periconceptional period. The study also aimed to
establish the factors associated with optimal FA supple-
mentation practices.
Methods
The present study was cross-sectional and observational,
conducted between January 2014 and April 2016. A total
of 856 women were recruited from the antenatal booking
clinic of the Coombe Women and Infants University
Hospital. This hospital is one of the largest maternity
hospitals in the European Union and cares for women
from all socio-economic groups and from across the
urban–rural divide. The sociodemographic characteristics
of our sample population are closely representative of the
broader population attending the hospital for antenatal
care(21) and also reflect the major sociodemographic
indicators of the national obstetric population(22). These
findings support the suitability of this sample population in
undertaking an investigation of FA supplementation
among pregnant women in Ireland(21,22).
Data collection
Women’s clinical and sociodemographic details were
computerised routinely at the first antenatal visit and
updated immediately after delivery. The inclusion criteria
for the current study were attendance for antenatal care
after ultrasound examination confirmed an ongoing
singleton pregnancy in the first trimester. The exclusion
criteria were multiple pregnancies, age less than 18 years
and an inability to understand English.
A convenience sample of women was recruited by a
trained research dietitian at their first antenatal visit. If the
woman agreed to participate in the study, she was
provided with the relevant questionnaires. These ques-
tionnaires were completed with the research dietitian,
taking approximately 20min. Table 1 details the socio-
demographic and other variables collected to characterise
the sample population, along with the instruments used to
collect these data. Table 2 describes the sub-categories for
each of the categorical variables collected.
Written informed consent was obtained from all study
participants. The study was approved by the Hospital’s
Research Ethics Committee (study reference number:
27-2013).
Folic acid questionnaire
The FA questionnaire included questions about the use of
FA both pre- and periconceptionally. Data were also col-
lected describing the stage of pregnancy at which FA
supplementation was commenced and the number of
weeks (both preconceptionally and postconceptionally)
for which the woman took FA. The questionnaire also
included questions about the dose and brand name of FA
used and compliance with the established minimum
duration of supplementation for optimal NTD prevention
(i.e. 12 weeks of preconceptional FA(8–10)).
Anthropometric data
Weight was measured digitally using a Tanita Body
Composition Analyser model MC-180MA III (Tanita Corp.,
Tokyo, Japan). Height was measured to the nearest
centimetre using a Seca wall-mounted digital metre
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Table 1 Variables examined and data collection protocols
Instrument Operationalisation Name of variables collected
Folic acid (FA) questionnaire Self-reported supplement use
Completed under the supervision of research dietitian
FA supplement information:
∙ Preconceptional use
∙ Postconceptional use
∙ Timing of commencement
∙ Compliance with
supplementation
∙ Brand of supplement used
∙ Dose of FA taken
Sociodemographic questionnaire Self-reported sociodemographic data
Completed under the supervision of research dietitian
Sociodemographic information:
∙ Place of birth
∙ Years spent living in Ireland
∙ Smoking status
∙ Years of full-time education
completed
∙ Age finished full-time education
∙ Relative income poverty
∙ Relative deprivation
∙ Consistent poverty
Tanita Body Composition Analyser, model
MC-180MA III (Tanita Corp., Tokyo, Japan)
The woman was instructed to stand in bare feet on the electrode panel for measurement. Feet were
positioned on the heel and toe electrodes on each side in roughly equal proportions. The woman was
then instructed to take the handle electrodes in her hands and place the arms straight down during
measurement. Contact between the arms and torso, and between the inner thighs, was avoided
Weight (kilograms)
Seca wall-mounted digital metre stick
(Seca, Birmingham, UK)
The woman was instructed to stand straight and to stretch with her heels against the measuring rod. The
woman’s head was placed in the Frankfort plane (top of the external ear canal and the lower bone of the eye
socket in a horizontal plane parallel to the floor). The head plate was lowered until it touched the top of the
head, compressing the hair. The woman was asked to inhale deeply and maintain a fully erect position, while
maintaining the head in the Frankfort position. Height was recorded to the nearest 0·1cm
Height (centimetres)
Computer medical system The hospital’s computerised medical system was accessed to obtain additional patient details ∙ Marital status
∙ Parity
∙ Planned pregnancy
∙ Assisted reproduction
∙ Booking gestation (weeks)
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stick with the woman standing in her bare feet (Seca,
Birmingham, UK). BMI was calculated.
Sociodemographic questionnaire
Maternal characteristics such as socio-economic status,
highest level of formal education, smoking status and
number of years spent living in Ireland were obtained
using the sociodemographic questionnaire. Information
on socio-economic status was derived using questions
from the Survey on Income and Living Conditions(23,24).
Material indices of disadvantage including relative income
poverty and relative deprivation status were assessed,
while consistent poverty status was also calculated. Rela-
tive income poverty status was determined by comparing
equivalised household income against the 60% median
income threshold. Relative deprivation was assessed by
determining whether respondents had experienced the
enforced absence (due to financial constraint) of two or
more basic necessities from a list of eleven over the past
year. Consistent poverty was identified if a respondent
reported being in relative income poverty, in addition to
experiencing the enforced absence of two or more of the
eleven basic markers of deprivation over the previous
year(24). The detailed algorithmic methods used for the
calculation of these indicators are available in a document
produced by the European Commission(23), and this
methodology has been adopted by the Irish Central
Statistics Office(24).
Statistical analysis
Data from the participant questionnaires were anonymised
and coded on a Microsoft Excel© spreadsheet. Where
appropriate, continuous variables were collapsed into
categorical variables. The distribution of continuous data
was assessed for normality by assessing the kurtosis and
skewness of their distribution, the associated Kolmo-
gorov–Smirnov statistics, and by a visual inspection of the
distribution histogram and boxplot.
Descriptive statistics were first used to describe the
characteristics of the study cohort. Inferential cross-
tabulation with χ2 tests for independence were then
used to analyse differences in categorical variables (e.g.
compliance with FA supplementation for ≥12 weeks pre-
conceptionally) between different population groups.
Finally, binary logistic regression analyses were performed
to assess the independent association of a number of
putative predictor variables with the likelihood of using FA
for ≥12 weeks preconceptionally. Factors were included
in the multivariate model based on their significant asso-
ciation with the use of FA for ≥12 weeks pre-
conceptionally upon univariate analysis (P< 0·05). In total,
nine variables were included in the model: age, parity,
marital status, smoking status, use of assisted reproduc-
tion, whether the pregnancy was planned or unplanned,
years of full-time education completed, relative income
poverty status and consistent poverty status.
Results
Table 2 shows the clinical and sociodemographic char-
acteristics of the study population. This study population is
largely representative of the hospital and national obstetric
populations(21,22).
Table 3 shows the duration and dosage of FA supple-
mentation before the confirmation of pregnancy at the first
antenatal visit. While almost all women (97%) were taking
FA at this stage of their pregnancy, only one in four
women took FA for at least 12 weeks preconceptionally
(24%; 208/850).
Of the women who took FA for any duration before
pregnancy (44%; n 375), 370/375 reported the number of
weeks preconceptionally for which they had used FA.
Of these 370, 56% (208/370) took FA for ≥12 weeks
preconceptionally.
Of the women who took FA only after becoming
pregnant (n 453), 443 (98%) reported the stage of preg-
nancy at which they started taking FA. Of these 443
women who took FA only after becoming pregnant, the
median stage of gestation at which FA supplementation
commenced was 5·2 weeks (36 d post conception), and
61% (270/443) started taking FA more than 28 d post-
conception (i.e. after the closure of the neural tube). Of
the 828 women who reported taking FA during their
pregnancy, data describing compliance with supplement
use existed for 822. Of these women, 97% (796/822)
reported daily supplement use.
The women used a wide range of FA only and multi-
vitamin supplements (Table 4). No woman used a generic
multivitamin which contained 200 µg FA; the majority used
either a prenatal multivitamin (400 µg FA) or an isolated FA
only supplement (400 µg FA). Fourteen women (1·69%;
14/828) reported taking Galfar FA.
On further univariate analyses, the factors positively asso-
ciated with FA supplementation for ≥12 weeks pre-
conceptionally were increasing maternal age, being married,
nulliparity, planned pregnancy, assisted reproduction and
increasing level of education. Smoking, relative income
poverty and consistent poverty were negatively associated
with taking FA for ≥12 weeks preconceptionally (Table 5).
When binary logistic regression analysis was applied to
assess the factors associated with FA supplement use for
≥12 weeks preconceptionally, only planned pregnancy
(P< 0·001) and nulliparity (P= 0·002) remained positively
associated with this optimal duration of supplementation
(Table 6). Fewer than half of the women in the total cohort
were included in this model, as data describing years of
full-time education were collected on only 485 of the 856
women. Another factor which contributed to the smaller
sample size for the multivariate model was the inclusion of
consistent poverty as an independent variable in the
model. The calculation of consistent poverty requires the
presence of both relative income poverty and deprivation
status data. Previous studies have shown that many people
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are reluctant to answer questions regarding their income,
and also that they may not remember or know exactly
what their income is, particularly if it is expressed on a
monthly basis(25,26). In the current study, data for con-
sistent poverty could be derived for only 531 of the 856
study participants.
Discussion
The current cross-sectional observational study of 856
women presenting for antenatal care found that almost all
women (97%) reported taking FA during their pregnancy.
However, only one in four women had taken FA for at least
12 weeks before conception. Of those who started taking FA
only after becoming pregnant, almost two-thirds reported
starting FA after day 28 of gestation; that is, after the neural
tube had closed (Table 3). On multivariate analysis only
planned pregnancy and nulliparity remained significantly
associated with taking FA for at least 12 weeks pre-
conceptionally. This contemporary information is important
for the design and dissemination of forthcoming public
health campaigns intended to improve maternal FA sup-
plementation practices and folate levels before and after
conception.
Table 2 Characteristics of the study population (n 856) presenting
for antenatal care at a large university maternity hospital, Republic
of Ireland, January 2014–April 2016
Mean, % or
median
SD, n or
IQR
Age (years), mean and SD 30·7 5·5
Weight (kg)*, mean and SD 69·5 15·5
BMI (kg/m2)*, mean and SD 25·8 5·4
BMI category, % and n
Underweight 1·8 15
Normal weight 52·3 448
Overweight 28·2 241
Obese 17·5 149
Obese class 1 11·0 94
Obese class 2 4·6 39
Obese class 3 1·9 16
Parity*, % and n
Nulliparous 39·3 335
Marital status†, % and n
Married 52·2 445
Smoking‡, % and n
Current smoker 12·6 108
Former smoker 35·6 304
Never smoked 51·8 443
Level of education§, % and n
No formal education/primary education/
upper secondary
30·5 257
Technical or vocational qualification or
third level, non-degree (national
certificate, diploma from NCEA/Institute
of Technology or equivalent)
27·6 232
Tertiary (degree level and higher) 41·9 352
Age finished continuous full-time education
(years)||, median and IQR
21 5
Relative income poverty¶, % and n
Yes 24·9 142
Relative deprivation**, % and n
Yes 9·4 78
Consistent poverty††, % and n
Yes 5·5 31
Infertility issues (assisted reproduction/PCOS/infertility treatment/
surgical issues/menstrual problems/endometriosis/premature
menopause)‡‡, % and n
Yes 14·2 121
Infertility treatment‡‡, % and n
Yes 2·9 25
Assisted reproduction‡‡, % and n
Yes 2·0 17
Planned pregnancy§§, % and n
Yes 62·9 535
Gestation at visit (weeks), median and IQR 12·3 1·5
Nativity||||, % and n
Irish-born 86·0 608
Years in Ireland¶¶, median and IQR 28·0 17
IQR, interquartile range; NCEA, National Council for Educational Awards;
PCOS, polycystic ovary syndrome.
*Data for 853 women.
†Data for 852 women.
‡Data for 855 women.
§Data for 841 women.
||Data for 490 women.
¶Data for 570 women.
**Data for 833 women.
††Data for 565 women.
‡‡Data for 854 women.
§§Data for 851 women.
||||Data for 707 women.
¶¶Data for 838 women.
Table 3 Folic acid (FA) supplementation practices among women
(n 856) presenting for antenatal care at a large university maternity
hospital, Republic of Ireland, January 2014–April 2016
% or
median
n or
IQR
Taking FA during the pregnancy, % and n
Yes 96·7 828
No 3·3 28
Time of commencement of FA in those who
started FA postconceptionally (n 443) (weeks
postconception)*, median and IQR
5·2 2
Commencement times in those who started FA postconceptionally
(n 443)*, % and n
1–28d postconception 39·1 173
5–8 weeks postconception 51·9 230
9–12 weeks postconception 8·4 37
13 weeks postconception 0·7 3
Taking FA preconceptionally, % and n
Yes 43·8 375
No 56·2 481
Taking FA≥12 weeks preconceptionally†, %
and n
Yes 24·5 208
No 75·5 642
Time of commencement of FA in those who
started FA preconceptionally (n 370) (weeks
preconception), median and IQR
12 18
Commencement times in those who started FA preconceptionally
(n 370)‡, % and n
1–4 weeks preconception 21·9 81
5–8 weeks preconception 16·8 62
9–11 weeks preconception 5·1 19
12–16 weeks preconception 22·4 83
17–24 weeks preconception 9·2 34
25–51 weeks preconception 6·8 25
>1 year preconception 17·8 66
*Of the 481 women who did not take FA preconceptionally, 453 took
FA postconceptionally and twenty-eight did not take FA at any point in
pregnancy; data on duration of postconceptional FA usage for 443/453.
†Data missing for six women.
‡Data on timing of commencement for 370 of the 375 women who reported
taking FA before the pregnancy.
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Previous studies in Ireland have shown that 84–96% of
women use FA at any time during their pregnancy(12–14,27).
Irish studies also showed that 19–44% of women start
FA supplementation before pregnancy(12–14,27,28). These
findings concur with data from the current study, which
show that almost all women were taking FA once they
found out that they were pregnant and that 44% were
taking FA for some duration before conception.
Previous Irish studies investigating the timing and duration
of FA supplementation preconceptionally showed that just
one in four women takes FA for the optimal ≥12 weeks prior
to conception(12,14). These data compare favourably with
findings from East London which showed that only 12% of
women were taking FA at any point preconceptionally(15).
These low rates of preconceptional FA use in East London
may have been influenced by the high percentage of ethnic
minority groups in the sample population; a factor which has
previously been associated with suboptimal supplementation
in other studies(18). In a separate Canadian investigation,
of those women who took FA preconceptionally, over
two-thirds took for ≥12 weeks preconceptionally(20), a
pattern consistent with current Canadian guidelines
which recommend that FA be taken for 3 months
preconceptionally(29). European guidelines regarding FA
supplementation do not currently feature an explicit
recommendation concerning the required duration of FA
supplementation preconceptionally. This suggests that there
is a need to update our national and European FA guidelines
to include a recommendation on the ideal timing of
FA preconceptionally, in view of the recent kinetic
studies in this area(7–10). This message should be incorpo-
rated into renewed public health campaigns in this area to
enhance the clinical effectiveness of periconceptional FA
supplementation.
This is important because recent kinetic studies suggest
that it takes at least 12 weeks to achieve the 1000 nmol/l
level of RBC folate which is associated with reduced risk of
NTD(7). Our study shows that one in four women reported
taking FA for 12 weeks or more before becoming preg-
nant. However, of the women who reported taking FA
before their pregnancy and who reported their duration of
preconceptional FA use (370/375), only 56·2% (208/370)
reported taking FA for 12 weeks or more pre-
conceptionally as is required to achieve these optimal RBC
folate levels for NTD prevention. This suggests that even
among those who are taking FA preconceptionally, dura-
tion of FA supplementation is suboptimal.
There is also a paucity of data examining the timing of
FA commencement postconceptionally. In our study, of
the women who started taking FA only after becoming
pregnant (n 453), 443 reported the point at which they
commenced FA supplementation. The median time for
commencement of supplementation among these women
was 5·2 (interquartile range 2) weeks (36 d) postconcep-
tion. Of the 443 women who supplemented only post-
conceptionally, 39·1% (173/443) reported starting FA
between days 1 and 28 of their pregnancy, and 51·9%
(230/443) reported starting supplementation between
weeks 5 and 8 of their pregnancy. This is important as the
gross anatomy of the fetal brain and spine develop fully in
the first few weeks of pregnancy (i.e. at 3–4 weeks’
gestation)(30). Studies from Ireland and internationally also
suggest that of those women who start FA post-
conceptionally, the majority commence supplementation
after the first month of gestation(12,15,19). It is possible that
most women begin FA at week 5 postconception because
this is when they first realise that they are pregnant.
However, at this stage of the pregnancy, they have sur-
passed the window of opportunity to achieve optimal
levels of RBC folate for NTD prevention(7–10).
There are limited Irish data investigating the brand of FA
supplements being taken by women. A previous study(12)
showed that the most popular brand was Clonfolic, a 400μg
FA/d mono-supplement, and this finding mirrors that of the
Table 4 Brand and retail price of folic acid (FA) supplements taken by women (n 828) presenting for antenatal care at a large university
maternity hospital, Republic of Ireland, January 2014–April 2016
Users
Brand FA % n Multivitamin/FA only Dose FA (µg) Price (€) Quantity Price per tablet (€)
Clonfolic 34·2 284 FA only 400 3·80 30 tablets 0·13
Pregnacare original 30·1 249 Multivitamin 400 6·49–9·69 30 tablets 0·26
Own brand FA only (Tesco/Boots) 8·3 69 FA only 400 0·50–2·99 90 tablets 0·01–0·03
Pregnacare Plus (n-3) 6·6 55 Multivitamin 400 17·99–19·99 28 tablets 0·67
Pharmaton Matruelle 0·6 5 Multivitamin 400 16·99 30 tablets 0·57
Seven Seas Pregnancy Plus 2·9 24 Multivitamin 400 5·99 28 tablets 0·21
Galfar FA 1·7 14 Multivitamin 350 3·13 28 tablets 0·11
Pregnacare max 0·8 7 Multivitamin 400 25·99 56 tablets 0·46
Centrum Pregnancy Care 1·2 10 Multivitamin 400 6·74 30 tablets 0·22
Berocca 0·8 7 Multivitamin 400 10·99 30 tablets 0·37
Kelkin Folic Acid 0·5 4 FA only 400 3·15 60 tablets 0·05
Santogen New Mother 0·4 3 Multivitamin 400 14·49 40 tablets 0·36
Purchased abroad 4·7 39 FA only/multivitamin Unknown Unknown –
Clonfolic (High Dose) 6·3 52 FA only 5000 Unknown – prescription only –
Unknown 0·7 6 – – – –
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current study which found that 34% of pregnant women
who supplemented took Clonfolic as their FA supplement
of choice. Our study showed that 6·3% of women were
taking high-dose FA supplements. The majority of women
supplementing with FA in the current study took a 400 μg/d
dose. Fourteen women (1·69%; 14/828) reported taking
Galfar FA which contains 350 μg FA, with none reporting a
lower dose of 200μg/d which would be more typical
of generic multivitamin supplements. A higher-dose FA
supplement is recommended for women considered to
be at higher risk of an NTD (e.g. those with a previous NTD-
affected pregnancy, those with diabetes)(5).
On multivariate analysis only planned pregnancy and
nulliparity were associated with taking FA for at least
12 weeks preconceptionally, echoing the findings of our
previous study(13) and suggesting that these factors are
important determinants not only of the decision to take FA
preconceptionally, but also of the duration for which women
take FA preconceptionally. Planned pregnancy has been
consistently positively associated with periconceptional FA
use(12,14,31); while lower parity has also been previously
shown to predict FA supplementation in the preconceptional
period(12,14,31,32). Unlike previous studies in the literature(33),
BMI was not associated with less favourable FA supple-
mentation practices at any time preconceptionally.
The present study has strengths. First, the information on
FA supplementation was recorded using a supervised
questionnaire completed at a personal consultation with a
single, trained dietetic researcher at the first antenatal visit.
This reduced the risks of respondent error, recall bias or
inter-observer variation. This supervised approach has
previously been shown to result in lower levels of recall bias
compared with self-administered questionnaires(34). Maternal
socio-economic, sociodemographic and anthropometric
data, including measured weight, height and BMI, were also
recorded accurately in a standardised way, enhancing the
integrity of those data(35). The study sample is also repre-
sentative of the broader national obstetric population from a
socio-economic and sociodemographic perspective(22),
increasing the applicability and relevance of our findings in
the broader public health context. A potential weakness of
the single-centre, convenience sampling method employed
in the present study is that the women recruited may differ
from the wider population. However, the hospital does
accept women from all socio-economic groups, and from
across the urban–rural divide, with roughly one in eight of all
births in the Republic of Ireland being delivered at this
hospital in 2013(21). The substantially increased time and
personnel costs associated with a consecutive sampling
protocol precluded the use of such recruitment techniques in
our study. However, by inviting all women attending the
hospital to take part in the study, we aimed to recruit a
sample population which was largely representative of the
national obstetric population; and our post hoc analyses
confirmed that this objective had been met. A further
challenge with all observational studies is the potential for
Table 5 Univariate analysis of factors associated with folic acid
(FA) supplementation for at least 12 weeks preconceptionally
among women (n 856) presenting for antenatal care at a large
university maternity hospital, Republic of Ireland, January 2014–
April 2016
Taking FA for ≥12 weeks
preconceptionally
% n P value
Age (years)*
<22 (n 54) 0 0 <0·001
22–30 (n 351) 17·9 63
>30 (n 445) 32·6 145
Married†
Yes (n 443) 33·2 147 <0·001
No (n 403) 14·9 60
Place of birth‡
Ireland (n 605) 26·1 158 0·303
Outside Ireland (n 97) 20·6 20
Years living in Ireland§
<5 (n 45) 11·1 5 0·099
5–10 (n 131) 23·7 31
>10 (n 657) 25·3 166
BMI (kg/m2)||
<18·5 (n 15) 13·2 2 0·694
18·5–24·9 (n 445) 25·8 115
25·0–29·9 (n 238) 23·1 55
30·0–34·9 (n 94) 22·3 21
35·0–39·9 (n 39) 30·8 12
≥40·0 (n 16) 18·8 3
Current smoker¶
No (n 741) 27·4 203 <0·001
Yes (n 108) 4·6 5
Parity**
Nulliparous (n 332) 30·4 101 0·002
Multiparous (n 515) 20·6 106
Planned pregnancy††
Yes (n 530) 35·8 190 <0·001
No (n 315) 5·4 17
Assisted reproduction‡‡
Yes (n 17) 76·5 13 <0·001
No (n 831) 23·3 194
Years of full-time education§§
≤15 (n 202) 16·3 33 <0·001
16–18 (n 180) 29·4 53
>19 (n 103) 41·7 43
Age finished full-time education§§
≤21 (n 281) 21 59 0·001
>22 (n 204) 34·2 70
Relative income poverty||||
Yes (n 142) 9·2 13 <0·001
No (n 425) 31·1 132
Relative deprivation¶¶
Yes (n 78) 19·2 15 0·164
No (n 750) 25·2 130
Consistent poverty***
Yes (n 138) 16·7 23 <0·001
No (n 393) 30·3 119
Significant P values are indicated in bold.
*Data for 850 women.
†Data for 846 women.
‡Data for 702 women.
§Data for 833 women.
||Data for 847 women.
¶Data for 849 women.
**Data for 847 women.
††Data for 845 women.
‡‡Data for 848 women.
§§Data for 485 women.
||||Data for 567 women.
¶¶Data for 828 women.
***Data for 531 women.
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confounding when evaluating the association between
individual factors and the outcome variable. However, this
was addressed by using multivariate statistical analyses.
Conclusion
In conclusion, the present study shows that even among
the 44% of women who are supplementing with FA pre-
conceptionally, 44% (162/370) report taking FA for less
than the required 12 weeks to achieve optimal RBC folate
levels for NTD prevention. Among those who take FA only
postconceptionally, the majority start supplementing after
day 28 of gestation, at which point the neural tube has
already closed. Given our finding that planned pregnancy
and nulliparity are the factors most strongly associated
with taking FA for at least 12 weeks preconceptionally, we
suggest that future public health campaigns should
encourage all women at risk of becoming pregnant, even
those not planning a pregnancy, to take FA prophylacti-
cally. The low rates of preconceptional FA supplementa-
tion observed in the present study, and the suboptimal
duration of preconceptional FA supplementation reported
among even those who do take FA prior to conception,
further emphasise the need for enhanced health messa-
ging in this area. The delayed stage at which post-
conceptional FA supplementation is typically initiated,
often at a time after the neural tube has already closed,
constitutes a further strong rationale for the promotion of
prophylactic FA supplementation in future public health
campaigns. In the future, we are confident that we will be
able to contribute to the knowledge gap which currently
exists between FA intake levels and RBC folate.
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